172
Participants
Start Date
November 30, 2002
Primary Completion Date
October 31, 2004
Study Completion Date
October 31, 2004
Degarelix
Degarelix (120 mg (20 mg/mL)) was given as a subcutaneous injection
Degarelix
Degarelix (120 mg (40 mg/mL)) was given as a subcutaneous injection
Degarelix
Degarelix (160 mg (40 mg/mL)) was given as a subcutaneous injection
Degarelix
Degarelix (200 mg (40 mg/mL)) was given as a subcutaneous injection
Degarelix
Degarelix (200 mg (60 mg/mL)) was given as a subcutaneous injection
Degarelix
Degarelix (240 mg (40 mg/mL)) was given as a subcutaneous injection
Degarelix
Degarelix (240 mg (60 mg/mL)) was given as a subcutaneous injection
Degarelix
Degarelix (320 mg (60 mg/mL)) was given as a subcutaneous injection
Rigshospitalet, Copenhagen
KAS Glostrup, Glostrup Municipality
KAS Herlev, Herlev
Marian Sairaala, Helsinki
P-K Keskussairaala, Joensuu
Vuorikadun lääkäriasema, Kuopio
OYS, Oulu
Kirugikeskus, Seinäjoki
TAYS, Tampere
Bajcsy-Zsilinszky Hospital, Urology, Budapest
Jahn Ferenc Dél Pesti Hospital, Urology, Budapest
Péterfy Hospital, Urology, Budapest
Bács-Kiskun County Hospital, Urology, Kecskemét
Hospital of Local Gov. Szeged, Urology, Szeged
MÁV Hospital, Urology, Szolnok
Sentralsykehuset i Rogland, Stavanger
CF2 Hospital - Bucharest, Urology, Bucharest
Dr. Th Burghele Hospital, Bucharest
Fundeni Hospital - Bucharest, Urology, Bucharest
County Hospital - Timisoara, Urology, Timișoara
City Hospital #1, State Med Univ/Urology, Moscow
Institute of Urology of MoH, Moscow
Moscow City Hospital #60, Urology, Moscow
City Hospital #15, Urology Department, Saint Petersburg
City Hospital #26, Urology Department, Saint Petersburg
Sahlgrenska Universitetssjukehuset, Gothenburg
Helsingborgs Lasaret, Helsingborg
Universitetssjukehuset, MAS, Malmo
University Hospital, Örebro, Örebro
Akademiska Sjukhuset Uppsala, Uppsala
Lead Sponsor
Ferring Pharmaceuticals
INDUSTRY